Observational studyJournal of pediatric gastroenterology and nutrition2026
Heterogeneous outcomes in pediatric potential celiac disease: A multicenter longitudinal study.
Observational study in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Heterogeneous outcomes in pediatric potential celiac disease: A multicenter longitudinal study.Journal of pediatric gastroenterology and nutrition · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesPotential celiac disease (PCD) is defined by positive celiac serology without villous atrophy. We aimed to study the outcome of children with PCD consuming a gluten-containing diet (GCD) over time.
methodsChildren diagnosed with PCD between December 2018 and January 2022, in three pediatric gastroenterology centers, were longitudinally followed. Data were collected until October 2024, with a minimum follow-up of 12 months, unless celiac disease (CeD) was diagnosed earlier. Baseline data included demographics, celiac serology, and histological findings. Follow-up data included serology and biopsy results when performed.
resultsThe cohort included 88 patients with PCD, with a mean follow-up of 39 (range 12- 69) months. During this period, 17 (19.5%) patients progressed to CeD. Normalization of anti-tissue transglutaminase antibodies (tTG), while continuing a GCD, occurred in 33/88 (37.5%) while the rest remained with PCD. Specifically, among 16 patients with tTG levels >×10 upper limit of normal (ULN) at PCD diagnosis, three (18.8%) progressed to CeD, six (37.5%) normalized tTG while continued GCD, and the rest remained unchanged. Asymptomatic patients had higher rates of tTG normalization (61.9% vs. 35.8%, p = 0.0011). Neither tTG levels, nor having Marsh 1 histology, had a significant effect on PCD outcomes.
conclusionsAmong pediatric patients with PCD, during a mean follow-up of 3.3 years, one-fifth progressed to CeD. Baseline serology levels do not reliably predict future mucosal deterioration. Over a third of children with PCD may achieve serological normalization while maintaining a GCD. This heterogeneous pattern of PCD warrants periodic serological and histological follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.